DAJY(SZ:002030)2023-07-06 09:14Group 1: Financial Performance - The company's accounts receivable for 2022 was approximately 4 billion, with Q1 2023 around 3.5 billion, indicating a good collection progress [2] - In 2021, the company invested 600 million in R&D, which increased to 1.1 billion in 2022 [2] - The company distributed over 2.4 billion in cash dividends to investors this year [2] Group 2: Business Strategy and Development - The company plans to expand its product lines into respiratory pathogens, gastrointestinal pathogens, reproductive health, and personalized medicine [2] - The company has enhanced its production capacity significantly, with daily output from PCR and POCT production lines increased compared to previous years [3] - The company employs a flexible production model based on market demand, reducing the risk of overcapacity [3] Group 3: Market Expansion and Innovation - The company aims to expand into overseas markets, focusing on regions with favorable economic conditions and open policies [3] - The company has a comprehensive production model, manufacturing raw materials, reagents, and equipment in-house [4] - The company emphasizes technological innovation and product development as key factors for success in the IVD industry [4] Group 4: Corporate Culture and Future Plans - The company's culture is rooted in "shared growth value," emphasizing technological innovation and scientific spirit [4] - The company plans to continue its strategy of "main business development + industrial incubation," focusing on biomedicine and health [4]